KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Deferred Taxes (2021 - 2025)

Halozyme Therapeutics (HALO) has disclosed Deferred Taxes for 9 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes rose 9.65% to $16.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$634000.0, a 19.17% decrease, with the full-year FY2025 number at -$634000.0, down 19.17% from a year prior.
  • Deferred Taxes was $16.8 million for Q4 2025 at Halozyme Therapeutics, up from -$27.4 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $142.5 million in Q3 2021 to a low of -$27.4 million in Q3 2025.
  • A 5-year average of $4.4 million and a median of -$2.6 million in 2023 define the central range for Deferred Taxes.
  • Biggest YoY gain for Deferred Taxes was 321.38% in 2025; the steepest drop was 9267.81% in 2025.
  • Halozyme Therapeutics' Deferred Taxes stood at $13.0 million in 2021, then tumbled by 213.3% to -$14.7 million in 2022, then skyrocketed by 35.79% to -$9.4 million in 2023, then surged by 262.28% to $15.3 million in 2024, then rose by 9.65% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Deferred Taxes are $16.8 million (Q4 2025), -$27.4 million (Q3 2025), and $7.1 million (Q2 2025).